With the proliferation of digital innovations, accessible data, and artificial intelligence, the time seems ripe for innovations to disrupt clinical trials. Despite these opportunities, trials today seem confounded by stalled recruitment, overwhelming volumes of data, and stretched resources. What are the greatest opportunities to remove these persistent barriers, and how can biotech agility outpace legacy pharma in adoption? From digitization to decentralization to automation and beyond, join Craig Lipset of Clinical Innovation Partners to explore how we modernize the clinical trial future patients deserve.